APOE Antibody Inhibits Aβ-Associated Tau Seeding and Spreading in a Mouse Model.
Maud GratuzeHong JiangChanung WangMonica XiongXin BaoDavid M HoltzmanPublished in: Annals of neurology (2022)
APOE is the strongest genetic factor for late-onset Alzheimer's disease (AD). A specific conformation of the ApoE protein is present in amyloid-β (Aβ) containing plaques. Immunotherapy targeting ApoE in plaques reduces brain Aβ deposits in mice. Here, we evaluated the effects of the anti-human APOE antibody HAE-4 on amyloid plaques, Aβ-mediated tau seeding and spreading, and neuritic dystrophy in the 5XFAD amyloid mice expressing human ApoE4. HAE-4 reduced Aβ plaques as well as Aβ-driven tau seeding/spreading and neuritic dystrophy. These results demonstrate that HAE-4 may provide therapeutic effects on amyloid removal and Aβ driven downstream consequences such as tauopathy. ANN NEUROL 2022;91:847-852.
Keyphrases
- cognitive decline
- high fat diet
- late onset
- early onset
- endothelial cells
- mild cognitive impairment
- mouse model
- cerebrospinal fluid
- induced pluripotent stem cells
- type diabetes
- gene expression
- adipose tissue
- pluripotent stem cells
- white matter
- insulin resistance
- drug delivery
- cancer therapy
- dna methylation
- brain injury
- multiple sclerosis
- copy number